Vertical Longevity Pharmaceuticals

Vertical Longevity Pharmaceuticals is an Irvine, California-based biotechnology company pioneering the first senolytic vaccine to target atherosclerosis at its root cause.

We are harnessing the power of virus-like particle (VLP) vaccines to eliminate senescent cells, one of the fundamental drivers of aging and chronic disease. Our immunotherapy offers a unique approach to reversing established plaque formation and restoring natural tissue function, moving beyond simply slowing the decline associated with cardiovascular disease.

What sets Vertical Longevity apart is our platform’s ability to target senescent cells durably, enabling a vaccine-mediated immune response that clears these cells and offers potential benefits across multiple organ systems – including pulmonary, renal, neurological, and structural tissues.

Currently, we are focused on confirming efficacy in upcoming primate studies, with the goal of demonstrating the first true cure for atherosclerosis. We are positioned at the intersection of cardiovascular, senolytic, and longevity markets, offering a cost-competitive intervention with the potential to redefine preventive care at a population level.